MedTrace Logo

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)

NCT00289198 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 301

Last updated 2018-04-13

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with perennial allergic rhinitis (PAR).

Conditions

  • Rhinitis, Allergic, Perennial

Interventions

DRUG

FF

fluticasone furoate 110 μg nasal spray

DRUG

Placebo

placebo nasal spray

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-07
Primary Completion
2006-07-01
Completion
2006-07-04

Countries

  • United States
  • Australia
  • Canada
  • Estonia
  • Germany
  • Latvia
  • Lithuania
  • New Zealand
  • Russia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00289198 on ClinicalTrials.gov